Antoon Ligtenberg

Title: Antoon Ligtenberg: Innovator in Medicinal Chemistry

Introduction

Antoon Ligtenberg is a notable inventor based in Amstelveen, Netherlands. He has made significant contributions to the field of medicinal chemistry, particularly in the treatment of diseases associated with sulphate and phosphate groups. His innovative work has led to the development of a unique patent that addresses critical health issues.

Latest Patents

Antoon Ligtenberg holds a patent titled "Use of DMBT1 for capturing sulphate and phosphate group exposing agents." This patent discloses the use of DMBT1, or the nucleic acid encoding it, for the manufacture of a medicament aimed at treating patients suffering from diseases caused by agents with accessible sulphate and/or phosphate groups. The patent also outlines the use of DMBT1 as a diagnostic tool for assessing an individual's susceptibility to these groups, along with methods for diagnosis, prophylaxis, or treatment of related diseases. He has 1 patent to his name.

Career Highlights

Antoon Ligtenberg is associated with the Deutsches Krebsforschungszentrum, a leading cancer research center. His work there focuses on innovative approaches to combat diseases, leveraging his expertise in medicinal chemistry. His research has the potential to impact the treatment landscape significantly.

Collaborations

Antoon collaborates with esteemed colleagues such as Jan Mollenhauer and Caroline End. Their combined efforts contribute to advancing research in the field and enhancing the understanding of disease mechanisms.

Conclusion

Antoon Ligtenberg's contributions to medicinal chemistry and his innovative patent demonstrate his commitment to improving healthcare outcomes. His work continues to inspire advancements in the treatment of diseases related to sulphate and phosphate groups.